Detalles de la búsqueda
1.
Treatment Outcomes of Second-Line Systemic Therapy for Neuroendocrine Prostate Cancer: A Report of Four Cases.
J UOEH
; 46(1): 23-28, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38479871
2.
Differential impact of proton pump inhibitor on survival outcomes of patients with advanced urothelial carcinoma treated with chemotherapy versus pembrolizumab.
Int J Urol
; 30(9): 738-745, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-36693764
3.
Analysis of fluoroquinolone-resistance using MIC determination and homology modelling of ParC of contemporary Mycoplasma genitalium strains.
J Infect Chemother
; 28(3): 377-383, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34836778
4.
[Clinical Statistics From 2017 to 2019 in the Department of Urology, Hospital of the University of the Occupational and Environmental Health, Japan].
J UOEH
; 44(2): 191-196, 2022.
Artículo
en Japonés
| MEDLINE | ID: mdl-35660685
5.
Combination therapy with paclitaxel and gemcitabine after platinum-based chemotherapy in patients with advanced urothelial cancer.
Int J Urol
; 28(9): 970-974, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-34240471
6.
Oncological Outcome After Radical Prostatectomy without Pelvic Lymph Node Dissection for Localized Prostate Cancer: Follow-up Results in a Single Institution.
Cancer Invest
; 37(10): 524-530, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31597501
7.
Premature Mortality Due to Malignancies of the Kidney and Bladder in Japan, 1980-2010.
J Epidemiol
; 29(12): 464-470, 2019 Dec 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30473546
8.
Reconsideration on Clinical Benefit of Pelvic Lymph Node Dissection during Radical Prostatectomy for Clinically Localized Prostate Cancer.
Urol Int
; 103(2): 125-136, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31039571
9.
Efficacy and Tolerability of Bacillus Calmette-Guérin Therapy as the First-Line Therapy for Upper Urinary Tract Carcinoma In Situ.
Cancer Invest
; 36(2): 152-157, 2018 Feb 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29393701
10.
Clinical Significance of Squamous Differentiation in Urothelial Carcinoma of the Bladder.
Cancer Control
; 25(1): 1073274818800269, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30213195
11.
Efficacy of Platinum-based Chemotherapy in Patients With Metastatic Urothelial Carcinoma With Variant Histology.
In Vivo
; 38(2): 873-880, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38418119
12.
Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study.
Curr Oncol
; 31(2): 862-871, 2024 02 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38392058
13.
Prostate-specific Antigen Kinetics During Androgen-deprivation Therapy Predict Response to Enzalutamide in Metastatic Castration-resistant Prostate Cancer.
Anticancer Res
; 43(1): 429-436, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36585210
14.
Small cell carcinoma of the kidney treated with immune checkpoint inhibitor/tyrosine kinase inhibitor.
IJU Case Rep
; 6(6): 386-389, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37928288
15.
Effect of Early Postoperative Rehabilitation on Length of Hospital Stay after Robot-assisted Radical Prostatectomy.
Prog Rehabil Med
; 8: 20230023, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37534203
16.
Initial-to-nadir Prostate-specific Antigen Ratio Predicts Response to First-line Enzalutamide in Metastatic Castration-resistant Prostate Cancer.
Anticancer Res
; 43(10): 4573-4581, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37772559
17.
Second-Line Systemic Therapy for Highly Aggressive Neuroendocrine Prostate Cancer.
Anticancer Res
; 43(9): 3841-3847, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37648316
18.
Efficacy and Tolerability of Enfortumab Vedotin for Metastatic Urothelial Carcinoma: Early Experience in the Real World.
Anticancer Res
; 43(9): 4055-4060, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37648337
19.
Association Between Body Mass Index and Outcomes in Patients With Urothelial Carcinoma Treated With Pembrolizumab.
Anticancer Res
; 43(1): 269-274, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36585166
20.
Prognostic Significance of 3-Month Prostate-specific Antigen Level Following Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer.
Anticancer Res
; 42(2): 1107-1114, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-35093913